Company intelligence / Profile preview
ExQor Technologies
Boston, Massachusetts, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
ExQor has demonstrated preclinical success in non-invasively delivering large molecule drugs to the brain using its proprietary clathrin transporter platform, achieving up to 300-fold improvement over conventional CNS delivery and advancing a unique biologic to restore cognitive ability via neuron regeneration. The company is preparing for its first IND filings for cognitive impairments, with ongoing development of personalized companion diagnostics for Alzheimer's and MCI[3][4].
- Therapeutic areas
- OncologyNeurologyEndocrinologyPsychiatry
- Modalities
- BiologicBio-nanoparticleNanotechnology
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ExQor Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExQor Technologies.